In vitro and In silico Analysis of β-lactam Derivatives as Antimycobacterial Agents
作者:Julieta Luna-Herrera、Edgar E. Lara-Ramirez、Ana R. Munoz-Duarte、Fabian E. Olazaran、Manuel J. Chan-Bacab、Rosa Moo-Puc、Alondra M. Perez-Vazquez、Cynthia M. Morales-Reyes、Gildardo Rivera
DOI:10.2174/1570180814666170106111316
日期:2017.6.30
Background: Tuberculosis is a worldwide public health threat, according to the World
Health Organization, 10.8 million people acquired the infection and 1.8 million deaths occurred due
to the disease in 2015. Currently, β-lactam derivatives have emerged as antituberculosis agents.
Objective: β-lactam derivatives were synthesized and tested in vitro against M. tuberculosis
(pan-susceptible and resistant strains) and macrophage cell line J77A.1.
Methods: Three series of β-lactam derivatives were synthetized following the Staudinger reaction of
an aromatic imine and an acid chloride. The antimycobacterial activity was carried out by the
microplate Alamar blue assay and cytotoxicity was assessed by the trypan blue exclusion assay on
macrophage cell line J774A.1. The software AutoDock Vina was used to perform molecular docking
studies of the synthesized drugs on the active site of the crystal structures of β -lactamase and
transpeptidase from M. tuberculosis.
Results: 7 β-lactam derivatives were effective against M. tuberculosis, including resistant strains. β-5
was the most active compound against the five strains (MIC= 3.125-6.25 μg/mL) with low
cytotoxicity. In silico analysis indicated the probable binding sites of the synthesized derivatives on
β-lactamase and transpeptidase.
Conclusion: β-lactam derivatives were effective on resistant M. tuberculosis strains with a low
cytotoxicity; therefore these compounds could be used for development new antitubercular agents.
背景:据世界卫生组织统计,2015 年有 1080 万人感染结核病,180 万人死于结核病。目前,β-内酰胺衍生物已成为抗结核药物。 目的:合成了β-内酰胺衍生物,并在体外对结核杆菌(泛感菌株和耐药菌株)和巨噬细胞系 J77A.1 进行了测试。 方法:三个系列的β-内酰胺衍生物:通过芳香族亚胺和酰氯的施陶丁格反应合成了三个系列的 β-内酰胺衍生物。抗霉菌活性采用微孔板阿拉玛蓝检测法,细胞毒性采用巨噬细胞系 J774A.1 的胰蓝排除法。使用 AutoDock Vina 软件对合成药物与结核杆菌β-内酰胺酶和转肽酶晶体结构的活性位点进行分子对接研究。 结果:7种β-内酰胺衍生物对结核杆菌(包括耐药菌株)有效。β-5是对五种菌株最有效的化合物(MIC= 3.125-6.25 μg/mL),但细胞毒性较低。硅学分析表明,合成的衍生物可能与β-内酰胺酶和转肽酶结合。 结论:β-内酰胺衍生物对耐药结核杆菌株有效,细胞毒性低,因此这些化合物可用于开发新的抗结核药物。